Combination therapies targeting HER2 and TME components, such as immune checkpoint inhibitors, angiogenesis inhibitors, and stromal-targeting agents, are being investigated in preclinical and clinical studies to improve treatment outcomes in HER2-positive breast cancer [101]. Here, ERBB2 is linked to breast cancer.